Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to $270.2 million.

  • Relay Therapeutics' Cash from Financing Activities fell 99.99% to $17,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $221.2 million, marking a year-over-year decrease of 24.04%. This contributed to the annual value of $270.2 million for FY2024, which is 677.35% up from last year.
  • Latest data reveals that Relay Therapeutics reported Cash from Financing Activities of $270.2 million as of FY2024, which was up 677.35% from $34.8 million recorded in FY2023.
  • In the past 5 years, Relay Therapeutics' Cash from Financing Activities ranged from a high of $426.5 million in FY2020 and a low of $34.8 million during FY2023.
  • Over the past 3 years, Relay Therapeutics' median Cash from Financing Activities value was $270.2 million (recorded in 2024), while the average stood at $198.3 million.
  • As far as peak fluctuations go, Relay Therapeutics' Cash from Financing Activities surged by 7,508.08% in 2020, and later slumped by 88.01% in 2023.
  • Yearly analysis of 5 years shows Relay Therapeutics' Cash from Financing Activities stood at $426.5 million in 2020, then dropped by 9.01% to $388.1 million in 2021, then fell by 25.30% to $289.9 million in 2022, then plummeted by 88.01% to $34.8 million in 2023, then soared by 677.35% to $270.2 million in 2024.